- Home
- CKPT vs IVA Comparison
CKPT vs IVA Comparison
Compare CKPT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- IVA
- Stock Information
- Founded
- CKPT 2014
- IVA 2011
- Country
- CKPT United States
- IVA France
- Employees
- CKPT N/A
- IVA N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- CKPT Health Care
- IVA Health Care
- Exchange
- CKPT Nasdaq
- IVA Nasdaq
- Market Cap
- CKPT 335.9M
- IVA 359.6M
- IPO Year
- CKPT 2017
- IVA 2020
- Fundamental
- Price
- CKPT $4.17
- IVA $3.62
- Analyst Decision
- CKPT Buy
- IVA Strong Buy
- Analyst Count
- CKPT 3
- IVA 4
- Target Price
- CKPT $4.33
- IVA $10.50
- AVG Volume (30 Days)
- CKPT 1.0M
- IVA 19.2K
- Earning Date
- CKPT 05-16-2025
- IVA 03-26-2025
- Dividend Yield
- CKPT N/A
- IVA N/A
- EPS Growth
- CKPT N/A
- IVA N/A
- EPS
- CKPT N/A
- IVA N/A
- Revenue
- CKPT $41,000.00
- IVA $14,591,573.00
- Revenue This Year
- CKPT $102,182.93
- IVA $15.38
- Revenue Next Year
- CKPT $351.71
- IVA $24.22
- P/E Ratio
- CKPT N/A
- IVA N/A
- Revenue Growth
- CKPT N/A
- IVA N/A
- 52 Week Low
- CKPT $1.47
- IVA $1.53
- 52 Week High
- CKPT $4.50
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- CKPT 71.99
- IVA 56.12
- Support Level
- CKPT $4.02
- IVA $3.40
- Resistance Level
- CKPT $4.17
- IVA $3.77
- Average True Range (ATR)
- CKPT 0.03
- IVA 0.25
- MACD
- CKPT -0.01
- IVA -0.04
- Stochastic Oscillator
- CKPT 93.33
- IVA 43.79
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.